CRISPR Therapeutics AG (CRSP) stock analysis
In our weekly check, CRISPR Therapeutics AG is graded F (A to F). Of 21 checks on debt, profit, cash flow and trend: 6 pass, warnings: 3, red flags: 12.
About CRISPR Therapeutics AG
CRISPR Therapeutics AG is a Healthcare company (Biotechnology) based in Switzerland, listed on NASDAQ as CRSP.
What our checks show for CRSP
Red flags
- The company has net debt but no positive operating earnings (EBITDA) to service it from (debt/equity 0.47).
- The net margin fell by 1853 points over 5 years, to -1812%: the company keeps less of each sale as profit.
- The gross margin fell by 766 points, to -677%: costs are rising faster than prices.
- Weak EPS forecast
- Earnings per share fell 17.2% a year over the last 3 years.
- The company is losing money.
- Free cash flow is negative: the business spends more cash than it brings in.
- The price swings a lot: 58% annual volatility. Expect large ups and downs.
- The stock has fallen as much as 85% from a peak. Would you have held through that?
- Beta 1.9: the stock usually moves more than the market, both up and down.
- Return on capital (ROCE) is zero or negative: the business does not earn on the money put into it.
- Free cash flow is negative, so no cash is left over to cover pay in shares.
Warning signs
- Operating cash flow is negative while the company reports a profit: the profit does not arrive as cash.
- The stock is still below its previous peak.
- The share count grew by 13.5% in 2 years: each shareholder owns a smaller slice.
Strengths
- Analysts expect revenue to grow about 274% a year over the next years.
- Analysts expect the net margin to improve by 1768 points from today's -1812%.
- Revenue grew 287% a year over the last 3 years.
Next earnings report: 2027-02-11
Similar companies
RLAY · XENE · TARS · AMLX · TNGX · DFTX
Questions
What grade does CRISPR Therapeutics AG (CRSP) have?
In our weekly check, CRISPR Therapeutics AG is graded F (A to F). Of 21 checks on debt, profit, cash flow and trend: 6 pass, warnings: 3, red flags: 12. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of CRSP stock?
This week's biggest flags for CRISPR Therapeutics AG: High debt, Margins falling, Gross margin falling. In total 15 of 21 checks show a warning or a red flag.
What does CRISPR Therapeutics AG do?
CRISPR Therapeutics AG is a Healthcare company (Biotechnology) based in Switzerland, listed on NASDAQ as CRSP.
When does CRISPR Therapeutics AG report earnings next?
The next earnings report is expected on 2027-02-11. We re-run the checks every week, so the grade can change after it.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis